Constantine Tam, MBBS, MD, Consultant Hematologist, Peter MacCallum Cancer Center, offers his impressions of the Phase 2 CAPTIVATE study investigating…
Browsing: Chronic Lymphocytic Leukemia
Tanya Siddiqi, MD, Director, CLL Program, Toni Stephenson Lymphoma Center, Associate Clinical Professor, Department of Hematology, City of Hope, elaborates…
Tanya Siddiqi, MD, Director, CLL Program, Toni Stephenson Lymphoma Center, Associate Clinical Professor, Department of Hematology, City of Hope, considers…
Tanya Siddiqi, MD, Director, CLL Program, Toni Stephenson Lymphoma Center, Associate Clinical Professor, Department of Hematology, City of Hope, offers…
John Seymour, MBBS, PhD, Professor, Director of the Department of Hematology, Peter MacCallum Cancer Centre, Melbourne Australia, considers whether minimal…
John Seymour, MBBS, PhD, Professor, Director of the Department of Hematology, Peter MacCallum Cancer Centre, Melbourne Australia, tells us about…
Ryan Lynch, MD Assistant Professor of Medicine, Hematology/Oncology, University of Washington, @SeattleCCA offers opinion on how physicians should be thinking…
Ryan Lynch, MD Assistant Professor of Medicine, Hematology/Oncology, University of Washington, @SeattleCCA considers whether minimal residual disease (MRD) is a…
Ryan Lynch, MD Assistant Professor of Medicine, Hematology/Oncology, University of Washington, @SeattleCCA tells us about the four-year update on the…
Lori Leslie, MD Medical Oncologist, Regional Cancer Care Associates, discusses how physicians should be thinking about the use of BTK…
John Burke, MD Physician, Associate Chair, US Oncology Hematology Research Program, Medical Oncology/ Hematology, Rocky Mountain Cancer Centers discusses the…
John Burke, MD Physician, Associate Chair, US Oncology Hematology Research Program, Medical Oncology/ Hematology, Rocky Mountain Cancer Centers outlines the…
John Burke, MD Physician, Associate Chair, US Oncology Hematology Research Program, Medical Oncology/ Hematology, Rocky Mountain Cancer Centers discusses how…
– If approved by the European Commission (EC), VENCLYXTO® plus obinutuzumab would be the first chemotherapy-free, combination regimen given with…
Robert Kreitman, MD of National Cancer Institute discusses Lumoxiti® phase III trial in patients with relapsed or refractory hairy cell…
Tanya Siddiqi, MD of @cityofhope discusses the updated results from transcend CLL 004, a Phase 1/2 study including patients with…
Jeff Sharman, MD of @TheUSONetwork discusses the phase III ELEVATE TN trial. _______ Read here:Â https://www.oncologytube.com/video/calquence-significantly-prolonged-the-time-patients-lived-without-disease-progression-or-death-in-previously-untreated-chronic-lymphocytic-leukemia?channelName=Cancer-News
Full results from Phase III ELEVATE TN trial showed 93% of patients on CALQUENCE combined with obinutuzumab vs. 47% of…
Mohamed Zaki, MD of @abbvie discusses the phase 3 MURANO trial. ________ Read here:Â https://www.oncologytube.com/video/new-long-term-data-continues-to-demonstrate-progression-free-survival-and-overall-survival-benefits-with-venclexta-venclyxto-venetoclax-combination-in-patients-with-relapsed-refractory-ch-1
Jennifer Crombie, MD of @DanaFarber discusses a phase I study of duvelisib and venetoclax in patients with relapsed or refractory…
John Seymour, PhD of @PeterMacCC discusses year analysis of murano study confirms sustained benefit of time-limited venetoclax-rituximab (VenR) in relapsed…
Thanos Zomas, MD of @TakedaOncology discusses brentuximab vedotin with chemotherapy for stage 3/4 classical hodgkin lymphoma (cHL): 4-year update of…
Con Tam, MD of @PeterMacCC discusses the phase 2 CAPTIVATE clinical trial in CLL.: how this will affect clinicians and…
Con Tam, MD of @PeterMacCC discusses the phase 2 CAPTIVATE clinical trial in CLL.
– Four-year updated analysis from the MURANO trial showed an 81% reduction in the risk of disease progression or death…
Marco Montillo, MD of @ospniguarda discusses the phase III DUO study. _________ https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-announces-copiktratm-duvelisib-presentations-0 https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-announces-copiktratm-duvelisib-presentations
ASH 2016 Page 3 Maintenance Therapy in Chronic Lymphocytic Leukemia
ASH 2016 Page 2 Update on New Chronic Lymphocytic Leukemia Drugs
ASH 2016 Page 1 Long Term Follow-up with Ibrutinib in CLL Patients
CLL, What is the significance of IGHV mutations and how are they assessed
Not Your Fathers CLL with Dr. John Pagel
CLL, Is there a role still for chemo AND who should get chemo
CLL, FCR vs BR Is One Better
Paul M. Barr MD, Associate Professor of Medicine at Wilmot Cancer Institute elaborates on the role of CAR-T cell therapy…
Paul M.Barr MD Associate Professor of Medicine at Wilmot Cancer Institute explains the results found of the RESONATE Trial that…
Paul M. Barr MD Associate Professor of Medicine at Wilmot Cancer Institute discusses the data found in the recent CLL-14…
Paul M. Barr MD Associate Professor of Medicine at Wilmot Cancer Institute provides his opinion on ibrutinib in 1st line…
Rod Humerickhouse discusses the importance of Minimal Residual Disease Negativity. Background: The multinational, open-label, phase 3 CLL14 trial compared fixed-duration…
Earn CME: https://naccme.com/program/7330 In this presentation from the ‘CLL in the Era of Targeted Therapy’ symposium at the 2019 Great…
Earn CME: https://naccme.com/program/7330 In this presentation from the ‘CLL in the Era of Targeted Therapy’ symposium at the 2019 Great…
Earn CME: https://naccme.com/program/7330 In this presentation from the ‘CLL in the Era of Targeted Therapy’ symposium at the 2019 Great…
Rod A. Humerickhouse, MD, PhD, Group Project Leader, Oncology Development, AbbVie, discusses Potential Side Effects From Venetoclax + Rituximab In…
Rod A. Humerickhouse, MD, PhD, Group Project Leader, Oncology Development, AbbVie, discusses MRD As A Surrogate Marker In CLL. At…
Jeff Sharman, MD, Director of Research, Willamette Valley Cancer Institute, Medical Director of Hematology Research, The US Oncology Network, discusses…
Jeff Sharman, MD, Director of Research, Willamette Valley Cancer Institute, Medical Director of Hematology Research, The US Oncology Network, discusses…
Carol Moreno, MD, PhD, Hematologist, University of Barcelona, discusses Outcomes Of The illUMINTATE Trial. At The 60th ASH Annual Meeting…
Rod A. Humerickhouse, MD, PhD, Group Project Leader, Oncology Development, AbbVie, discusses Testing For Minimal Residual Disease In CLL. At…
Jeff Sharman, MD, Director of Research, Willamette Valley Cancer Institute, Medical Director of Hematology Research, The US Oncology Network, Discusses…
Carol Moreno, MD, PhD, Hematologist, University of Barcelona, discusses Phase 3 Trial Examining Ibrutinib + Rituximab Versus FCR. At The…
Rod A. Humerickhouse, MD, PhD, Group Project Leader, Oncology Development, AbbVie, discusses Treating CLL Patients With Venetoclax And Rituximab. At…